ARTICLE | Clinical News

U.S. Bioscience regulatory update

August 15, 1994 7:00 AM UTC

UBS's Hexalen (altretamine) received Canadian marketing approval to treat ovarian cancer as first-line therapy in combination with other anti-cancer agents, and as a single agent or in combination in patients who have not responded to, or have relapsed on, other chemotherapeutic regimens. ...